Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
暂无分享,去创建一个
S. Shariat | T. Habuchi | S. Egawa | C. Ohyama | Shunsuke Tsuzuki | K. Mori | S. Hatakeyama | J. Miki | K. Hata | S. Narita | T. Yanagisawa | T. Otsuka | Mahito Atsuta | T. Kimura | T. Sano | Yuya Iwamoto | Yuki Enei | M. Nakazono | K. Sakanaka | K. Iwatani | Hideomi Nishikawa | A. Matsukawa
[1] S. Egawa,et al. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer , 2021, The Prostate.
[2] G. Haas,et al. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) , 2021, Annals of Oncology.
[3] K. Bevans,et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. D'Amico,et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] Henk G van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.
[6] R. V. D. van den Bergh,et al. Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment. , 2020, European urology focus.
[7] T. Habuchi,et al. Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective study , 2020, International journal of urology : official journal of the Japanese Urological Association.
[8] John L Pfail,et al. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial , 2020, Prostate Cancer and Prostatic Diseases.
[9] A. Briganti,et al. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.
[10] S. Shariat,et al. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis , 2019, International Journal of Clinical Oncology.
[11] M. Sydes,et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Stockler,et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[13] D. Ye,et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.
[14] H. Miyake,et al. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer , 2019, AntiCancer Research.
[15] D. Lam,et al. A Territory‐wide, Multicenter, Age‐ and Prostate‐specific Antigen‐matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone‐sensitive Prostate Cancer , 2019, Clinical genitourinary cancer.
[16] M. Gleave,et al. The impact of time to metastasis on overall survival in patients with prostate cancer , 2018, World Journal of Urology.
[17] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Kantoff,et al. Clinical Outcomes of First‐line Abiraterone Acetate or Enzalutamide for Metastatic Castration‐resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone‐sensitive Prostate Cancer , 2017, Clinical genitourinary cancer.
[19] S. Egawa,et al. Lactate dehydrogenase predicts combined progression‐free survival after sequential therapy with abiraterone and enzalutamide for patients with castration‐resistant prostate cancer , 2017, The Prostate.
[20] S. Culine,et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.
[21] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[22] A. Oronsky,et al. Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance , 2015, Neoplasia.
[23] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[24] Takahito Hara,et al. Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.
[25] P. Austin,et al. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.
[26] H. Akaza,et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. , 2008, Japanese journal of clinical oncology.
[27] Peter C Austin,et al. The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.
[28] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[29] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[30] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[31] H. Rao. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients , 1995, The Lancet.
[32] Seung Woo Lee,et al. Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs) , 2019, Medicine.
[33] Practicum Summary. University of Texas Southwestern Medical Center Dallas, TX , 2013 .
[34] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[35] M. Soloway,et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.